The 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC 2025) is dedicated to insulin resistance, obesity, diabetes, related Kidney, cardiovascular disease and fatty liver morbidity.

Topics

• The effect of lipotoxicity and the pathophysiology of CVD
• The relationship between diabetes, obesity, and congestive heart failure
• The roles of diabetes in the development of micro & macrovascular conditions: kidney disease, retinopathy, neuropathy, CVD and strokes
• The role of obesity in the development of cardiometabolic conditions
• The role of incretins in the management of diabetes, obesity, and related complications
• Comprehensive management of diabetes, through addressing obesity, hypertension, dyslipidemia and hyperglycemia
• The role of SGLT2i & GLP1ra for primary prevention of cardiovascular morbidity & mortality in patients with T2D
• The evidence supporting the use of SGLT2 inhibitors and GLP1ra`s to reduce cardiovascular morbidity & mortality in patients with T2D and established CVD
• Fatty liver disease and its relationship to diabetes and CVD
• The role of PCSK9 inhibitors in preventing CV morbidity in people with established ASCVD
• The impact on clinical practice of recent CVD, CHF & CKD outcome trials
• The pathogenesis of liver and muscle insulin resistance, the role of adipose tissue and of the mitochondria in hyperglycemia and ASCVD
• Best practices for the prevention and management of CHF
• The impact on clinical practice of lipid CV outcome trials, including IMPROVE -IT, FOURIER, REDUCE -IT, ODYSSEY-Outcomes
• The role of Coagulation and new anti-coagulation agents in prevention of CVD and CVA
• The Cardiorenal Syndrome
• Reducing morbidity and mortality through being able to match the correct medications to the appropriate patients

Who should Attend

• Endocrinologists
• Cardiologists
• Oncologists
• Gastroenterologists
• Diabetologists
• Internists
• Pediatricians
• OBGYNs
• Nurse practitioners
• Dietitians
• Pharmacists
• Other health care professionals